Vor Biopharma Inc. (NYSE:VOR) Insider Eyal C. Attar Sells 10,334 Shares of Stock

Vor Biopharma Inc. (NYSE:VOR) insider Eyal C. Attar sold 10,334 shares of Vor Biopharma stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $1.25, for a total value of $12,917.50. Following the completion of the transaction, the insider now owns 81,439 shares in the company, valued at approximately $101,798.75. This represents a 11.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Vor Biopharma Trading Down 6.7 %

Vor Biopharma stock traded down $0.08 on Tuesday, hitting $1.11. 812,418 shares of the stock traded hands, compared to its average volume of 538,518. The business’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $0.89. The firm has a market cap of $76.23 million, a P/E ratio of -0.67 and a beta of -0.37. Vor Biopharma Inc. has a 1 year low of $0.63 and a 1 year high of $3.14.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). As a group, analysts predict that Vor Biopharma Inc. will post -1.55 earnings per share for the current year.

Analysts Set New Price Targets

VOR has been the subject of several recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Robert W. Baird lowered their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vor Biopharma currently has an average rating of “Buy” and a consensus target price of $11.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC lifted its stake in shares of Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after buying an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the 2nd quarter worth approximately $53,000. Rosalind Advisors Inc. bought a new position in Vor Biopharma in the 3rd quarter valued at approximately $54,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vor Biopharma during the 2nd quarter valued at $63,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares in the last quarter. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.